TIDMGWP
RNS Number : 8715J
GW Pharmaceuticals PLC
18 June 2014
SOLELY FOR DISTRIBUTION OUTSIDE THE UNITED STATES
GW Pharmaceuticals Announces Proposed Public Offering of
ADSs
London, UK, 18 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH,
AIM: GWP, "GW" or the "Company"), a biopharmaceutical company
focused on discovering, developing and commercializing novel
therapeutics from its proprietary cannabinoid product platform,
announced today that it and certain of its shareholders intend to
sell, subject to market and other conditions, 1.7 million American
Depositary Shares ("ADSs") representing ordinary shares of GW on
the NASDAQ Global Market in an underwritten U.S. public offering.
GW will grant the underwriters a 30-day option to purchase up to an
additional 255,000 ADSs at the offering price. There can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering. The price for the
offering has not yet been determined.
Morgan Stanley, BofA Merrill Lynch and Cowen and Company are
acting as joint book-running managers for the offering. Piper
Jaffray is acting as lead manager.
The ADSs described above are being offered by GW and the selling
shareholders pursuant to a shelf registration statement filed by GW
with the Securities and Exchange Commission ("SEC") that became
automatically effective on May 7, 2014. Selling shareholders
comprise various directors of the Company. A preliminary prospectus
supplement related to the offering has been filed with the SEC and
is available on the SEC's website at http://www.sec.gov. Copies of
the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from Morgan
Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, New York 10014; BofA Merrill Lynch, 222 Broadway,
New York, NY 10038, attention: Prospectus Department, email:
dg.prospectus_requests@baml.com; or from Cowen and Company, c/o
Broadridge Financial Services, 1155 Long Island Avenue, Edgewood,
NY, 11717, Attn: Prospectus Department; or from Piper Jaffray,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
There will be no offer of ADSs to the public in the UK. This
press release is not directed to, or intended for distribution or
use by, any person or entity that is a citizen or resident or
located in any locality, state, country or other jurisdiction where
such distribution, publication, availability or use would be
contrary to law or regulation or which would require any
registration or licensing within such jurisdiction.
The distribution of this press release into jurisdictions other
than the UK may be restricted by law. Persons into whose possession
this announcement come should inform themselves about and observe
any such restrictions.
For readers in the European Economic Area
In any EEA Member State that has implemented the Prospectus
Directive, this communication is only addressed to and directed at
qualified investors in that Member State within the meaning of the
Prospectus Directive. The term "Prospectus Directive" means
Directive 2003/71/EC (and amendments thereto, including Directive
2010/73/EU, to the extent implemented in each relevant Member
State), together with any relevant implementing measure in the
relevant Member State.
For readers in the United Kingdom
This communication, in so far as it constitutes an invitation or
inducement to enter into investment activity (within the meaning of
s21 Financial Services and Markets Act 2000 as amended) in
connection with the securities which are the subject of the
offering described in this press release or otherwise, is being
directed only at (i) persons who are outside the United Kingdom or
(ii) persons who have professional experience in matters relating
to investments who fall within Article 19(5) ("Investment
professionals") of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) certain
high value persons and entities who fall within Article 49(2)(a) to
(d) ("High net worth companies, unincorporated associations etc")
of the Order; or (iv) any other person to whom it may lawfully be
communicated (all such persons in (i) to (iv) together being
referred to as "relevant persons"). The ADSs are only available to,
and any invitation, offer or agreement to subscribe, purchase or
otherwise acquire such ADSs will be engaged in only with, relevant
persons. Any person who is not a relevant person should not act or
rely on this document or any of its contents.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R), which is approved for
the treatment of spasticity due to multiple sclerosis in 25
countries outside the United States. Sativex is also in Phase 3
clinical development as a potential treatment of pain in people
with advanced cancer. This Phase 3 program is intended to support
the submission of a New Drug Application for Sativex in cancer pain
with the U.S. Food and Drug Administration and in other markets
around the world. GW has a deep pipeline of additional cannabinoid
product candidates, including Epidiolex which has received Orphan
Drug Designation from the FDA for the treatment of Dravet and
Lennox-Gastaut syndromes, severe, drug-resistant epilepsy
syndromes. GW's product pipeline also includes compounds in Phase 1
and 2 clinical development for glioma, ulcerative colitis, type--2
diabetes, and schizophrenia. For further information, please visit
www.gwpharm.com.
Forward-looking statements
This news release may contain forward-looking statements that
reflect GWs current expectations regarding future events, including
statements regarding the timing of and potential listing of
American Depository Shares on the NASDAQ Global Market, the
proposed timing of such offering and development and regulatory
clearance of the GW's products. Forward-looking statements involve
risks and uncertainties. Actual events could differ materially from
those projected herein and depend on a number of factors, including
(inter alia), the success of the GW's research strategies, the
applicability of the discoveries made therein, the successful and
timely completion of uncertainties related to the regulatory
process, and the acceptance of Sativex(R) , Epidiolex(R) and other
products and product candidates by consumer and medical
professionals. A further list and description of risks,
uncertainties and other risks associated with an investment in GW
can be found in GW's filings with the U.S. Securities and Exchange
Commission, including its shelf registration statement and the
documents incorporated by reference therein. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. GW undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980
557000
Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500
(US) 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen
(UK) + 44 20 3727 1000
Robert Stanislaro (US) 212 850 5657
Trout Group, LLC (US investor relations)
Todd James / Chad Rubin 646 378 2900
Peel Hunt LLP (UK NOMAD)
James Steel / Clare Terlouw +44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEFRMTTMBBBTII
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024